.Attributes Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint requires addition of people along with MASLD as well as size of liver outcomes in cardio-- kidney-- metabolic trials, when information propose mechanistically tenable advantages as well as medical safety-- and describes factors to consider for trial design as well as regulative approval.